Patrick Lin Processa Pharmaceuticals, Inc. (PCSA) insider trading activity

Patrick Lin is Chief Business - Strategy Off of Processa Pharmaceuticals, Inc.. Currently has a direct ownership of 29,059 shares of PCSA, which is worth approximately $33,708. The most recent transaction as insider was on Jul 10, 2024, when has been sold 271 shares (Common Stock) at a price of $1.71 per share, resulting in proceeds of $463. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 29.1K

0% 3M change

93.81% 12M change

Total Value Held $33,708

Patrick Lin Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 10 2024	SELL Payment of exercise price or tax liability	$463 $1.71 p/Share	271 Reduced 0.92%	29,059 Common Stock
Jul 10 2024	BUY Exercise of conversion of derivative security	-	644 Added 2.15%	29,330 Common Stock
Apr 05 2024	SELL Payment of exercise price or tax liability	$1,503 $2.79 p/Share	539 Reduced 1.84%	28,686 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	-	1,675 Added 5.42%	29,225 Common Stock
Feb 01 2024	BUY Open market or private purchase	$3,600 $2.4 p/Share	1,500 Added 5.18%	27,478 Common Stock
Jan 31 2024	BUY Open market or private purchase	$5,925 $2.37 p/Share	2,500 Added 8.78%	25,978 Common Stock
Jan 01 2024	SELL Payment of exercise price or tax liability	$1,503 $2.79 p/Share	539 Reduced 1.85%	28,614 Common Stock
Jan 01 2024	BUY Exercise of conversion of derivative security	-	1,675 Added 5.43%	29,153 Common Stock
Oct 12 2023	BUY Grant, award, or other acquisition	$1,600 $0.32 p/Share	5,000 Added 1.05%	469,535 Common Stock
Oct 10 2023	BUY Grant, award, or other acquisition	$2,877 $0.21 p/Share	13,700 Added 2.86%	464,535 Common Stock
Feb 09 2023	BUY Grant, award, or other acquisition	$10,000 $0.8 p/Share	12,500 Added 2.7%	450,835 Common Stock
Aug 05 2022	SELL Payment of exercise price or tax liability	$8,420 $3.17 p/Share	2,656 Reduced 0.6%	438,335 Common Stock
Aug 05 2022	BUY Exercise of conversion of derivative security	-	7,601 Added 1.69%	440,991 Common Stock
May 17 2022	BUY Open market or private purchase	$3,180 $1.59 p/Share	2,000 Added 0.46%	433,390 Common Stock
Apr 07 2022	BUY Open market or private purchase	$2,832 $3.54 p/Share	800 Added 0.19%	431,390 Common Stock
Apr 06 2022	BUY Open market or private purchase	$3,756 $3.13 p/Share	1,200 Added 0.28%	430,590 Common Stock
Dec 14 2021	BUY Open market or private purchase	$12,000 $4.0 p/Share	3,000 Added 0.69%	429,390 Common Stock
Dec 14 2021	BUY Open market or private purchase	$12,000 $4.0 p/Share	3,000 Added 0.69%	429,390 Common Stock
Dec 03 2021	BUY Open market or private purchase	$16,800 $4.8 p/Share	3,500 Added 0.81%	426,390 Common Stock
Aug 26 2021	BUY Open market or private purchase	$24,080 $6.02 p/Share	4,000 Added 0.94%	422,890 Common Stock
Aug 05 2021	BUY Grant, award, or other acquisition	-	7,601 Added 1.78%	418,890 Common Stock
Jun 21 2021	BUY Open market or private purchase	$13,300 $6.65 p/Share	2,000 Added 0.5%	401,737 Common Stock
Oct 01 2020	BUY Open market or private purchase	$65,625 $2.1 p/Share	31,250 Added 7.25%	399,737 Common Stock

Patrick Lin

Chief Business - Strategy Off

Hanover, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PCSA shares.

Notify only if

Value

Insider Trading

Get notified when an Processa Pharmaceuticals, Inc. insider buys or sells PCSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Processa Pharmaceuticals, Inc.

Track Activities on PCSA

Account